<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(5)</volume><submitter>Saad M</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>Cancer and diabetes are major public health concerns, with diabetes linked to increased cancer-related mortality. However, national trends and disparities remain underexplored.&lt;h4>Methods&lt;/h4>Using CDC WONDER data, we analysed deaths where both diabetes and cancer were listed as causes. Age-adjusted mortality rates (AAMRs) were calculated for diabetic cancer patients aged ≥ 25 years and stratified by demographics and geography. Joinpoint regression estimated annual percent changes (APCs) and average annual percent changes (AAPCs).&lt;h4>Results&lt;/h4>From 1999 to 2019, 699,007 cancer-related deaths occurred among individuals with diabetes. The overall AAMR increased from 15.06 to 15.23 per 100,000 (AAPC: +0.07%; p = 0.20), with a rise from 1999 to 2003, a decline from 2003 to 2015, and a resurgence from 2015 to 2019. Men (AAMR: 20.83) had higher mortality than women (AAMR: 11.80). Non-Hispanic Black individuals had the highest AAMRs (23.72), but NH American Indian/Alaska Natives had the largest increase (AAPC: 0.60). The Midwest (AAMR: 17.03) and rural areas (AAMR: 18.70) had the highest mortality, with rural rates rising significantly (AAPC: 0.92). Gastrointestinal cancers were the leading cause (AAMR: 4.31), followed by haematological (AAMR: 1.80), prostate (AAMR: 1.59), and breast cancer (AAMR: 1.38).&lt;h4>Conclusion&lt;/h4>Cancer-related mortality in individuals with diabetes has increased, with notable disparities. Targeted interventions, screening, and better diabetes management are essential to reducing risks in high-risk populations.</pubmed_abstract><journal>Endocrinology, diabetes &amp; metabolism</journal><pagination>e70092</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12463545</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Trends and Disparities in Cancer-Related Mortality Among Adults With Diabetes in the United States: 1999-2019.</pubmed_title><pmcid>PMC12463545</pmcid><pubmed_authors>Collins P</pubmed_authors><pubmed_authors>Arshad MS</pubmed_authors><pubmed_authors>Ali D</pubmed_authors><pubmed_authors>Batool RM</pubmed_authors><pubmed_authors>Saad M</pubmed_authors><pubmed_authors>Khan TM</pubmed_authors><pubmed_authors>Ahmed R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Trends and Disparities in Cancer-Related Mortality Among Adults With Diabetes in the United States: 1999-2019.</name><description>&lt;h4>Aim&lt;/h4>Cancer and diabetes are major public health concerns, with diabetes linked to increased cancer-related mortality. However, national trends and disparities remain underexplored.&lt;h4>Methods&lt;/h4>Using CDC WONDER data, we analysed deaths where both diabetes and cancer were listed as causes. Age-adjusted mortality rates (AAMRs) were calculated for diabetic cancer patients aged ≥ 25 years and stratified by demographics and geography. Joinpoint regression estimated annual percent changes (APCs) and average annual percent changes (AAPCs).&lt;h4>Results&lt;/h4>From 1999 to 2019, 699,007 cancer-related deaths occurred among individuals with diabetes. The overall AAMR increased from 15.06 to 15.23 per 100,000 (AAPC: +0.07%; p = 0.20), with a rise from 1999 to 2003, a decline from 2003 to 2015, and a resurgence from 2015 to 2019. Men (AAMR: 20.83) had higher mortality than women (AAMR: 11.80). Non-Hispanic Black individuals had the highest AAMRs (23.72), but NH American Indian/Alaska Natives had the largest increase (AAPC: 0.60). The Midwest (AAMR: 17.03) and rural areas (AAMR: 18.70) had the highest mortality, with rural rates rising significantly (AAPC: 0.92). Gastrointestinal cancers were the leading cause (AAMR: 4.31), followed by haematological (AAMR: 1.80), prostate (AAMR: 1.59), and breast cancer (AAMR: 1.38).&lt;h4>Conclusion&lt;/h4>Cancer-related mortality in individuals with diabetes has increased, with notable disparities. Targeted interventions, screening, and better diabetes management are essential to reducing risks in high-risk populations.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T20:17:53.378Z</modification><creation>2026-05-30T03:07:18.344Z</creation></dates><accession>S-EPMC12463545</accession><cross_references><pubmed>40998759</pubmed><doi>10.1002/edm2.70092</doi></cross_references></HashMap>